PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin(®)), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

BACKGROUND: PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin(®)) sourced from the EU (bevacizumab-EU), each with paclitaxel and carboplatin, in the first-line treatment of advanced non-squamous non-small-c...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BioDrugs
Hlavní autoři: Reinmuth, Niels, Bryl, Maciej, Bondarenko, Igor, Syrigos, Kostas, Vladimirov, Vladimir, Zereu, Manuela, Bair, Angel H., Hilton, Fiona, Liau, Katherine, Kasahara, Kazuo
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2019
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790355/
https://ncbi.nlm.nih.gov/pubmed/31338773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-019-00363-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky